Rekombinirani ili mokraćni humani korionski gonadotropin za konačno sazrijevanje jajnih stanica koje se pokreću u IVF i ICSI ciklusima
Appendices
Appendix 1. MDSG specialised register
HA413 Search string MDSG database 28.01.10
Keywords CONTAINS "recombinant HCG"or "recombinant LH"or "rh‐LH"or"rhCG"or"rhLH"or "r‐HCG"or"r‐hLH"or "r‐LH "or"rLH" or "Luveris" or "lutropin alfa" or "Lh recombinant" or Title CONTAINS "recombinant HCG"or "recombinant LH"or "rh‐LH"or"rhCG"or"rhLH"or "r‐HCG"or"r‐hLH"or "r‐LH "or"rLH" or "Luveris" or "lutropin alfa" or "Lh recombinant"
AND
Keywords CONTAINS "urinary HCG"or"u‐HCG "or "uHCG"or "Profasi" or "Pregnyl" or Title CONTAINS "urinary HCG"or"u‐HCG "or "uHCG"or "Profasi" or "Pregnyl"
Appendix 2. Cochrane Central Register of Controlled Trials (CENTRAL)
Database: EBM Reviews ‐ Cochrane Central Register of Controlled Trials <March 2015>
1 recombinant human chorionic gonadotropin$.tw. (21)
2 recombinant HCG.tw. (53)
3 rhCG.tw. (31)
4 r‐HCG.tw. (20)
5 rec hcg.tw. (2)
6 recombinant luteinizing hormone$.tw. (24)
7 recombinant luteinising hormone$.tw. (0)
8 recombinant LH.tw. (66)
9 rh‐LH.tw. (15)
10 rhLH.tw. (19)
11 r‐hLH.tw. (19)
12 r‐LH.tw. (16)
13 rLH.tw. (44)
14 Luveris.tw. (9)
15 lutropin alfa.tw. (5)
16 Lh recombinant.tw. (4)
17 recombinant human chorionic gonadotrophin$.tw. (10)
18 Luverisis.tw. (0)
19 LHadri.tw. (0)
20 recombinant human luteini?ing hormone$.tw. (23)
21 or/1‐20 (232)
22 urinary human chorionic gonadotropin$.tw. (11)
23 urinary human chorionic gonadotrophin$.tw. (4)
24 urinary HCG.tw. (30)
25 u‐HCG.tw. (11)
26 uHCG.tw. (11)
27 Profasi.tw. (9)
28 Pregnyl.tw. (3)
29 ovidrel.tw. (10)
30 Novarel.tw. (0)
31 choriogonadotropin alfa.tw. (1)
32 Follutein.tw. (0)
33 or/22‐32 (63)
34 21 and 33 (32)
35 limit 34 to yr="2010 ‐Current" (5)
Appendix 3. MEDLINE
Database: Ovid MEDLINE(R) <1946 to April 2015>
1 recombinant human chorionic gonadotropin$.tw. (47)
2 recombinant HCG.tw. (122)
3 rhCG.tw. (159)
4 r‐HCG.tw. (40)
5 rec hcg.tw. (1)
6 recombinant luteinizing hormone$.tw. (50)
7 recombinant luteinising hormone$.tw. (3)
8 recombinant LH.tw. (132)
9 rh‐LH.tw. (56)
10 rhLH.tw. (50)
11 r‐hLH.tw. (35)
12 r‐LH.tw. (52)
13 rLH.tw. (286)
14 Luveris.tw. (10)
15 lutropin alfa.tw. (22)
16 Lh recombinant.tw. (3)
17 recombinant human chorionic gonadotrophin$.tw. (23)
18 Luverisis.tw. (0)
19 LHadri.tw. (0)
20 recombinant human luteini?ing hormone$.tw. (42)
21 or/1‐20 (849)
22 urinary human chorionic gonadotropin$.tw. (75)
23 urinary human chorionic gonadotrophin$.tw. (28)
24 urinary HCG.tw. (247)
25 u‐HCG.tw. (38)
26 uHCG.tw. (17)
27 Profasi.tw. (29)
28 Pregnyl.tw. (44)
29 ovidrel.tw. (11)
30 Novarel.tw. (1)
31 choriogonadotropin alfa.tw. (8)
32 Follutein.tw. (1)
33 or/22‐32 (438)
34 21 and 33 (56)
35 randomized controlled trial.pt. (392496)
36 controlled clinical trial.pt. (89281)
37 randomized.ab. (317233)
38 placebo.tw. (165709)
39 clinical trials as topic.sh. (172346)
40 randomly.ab. (228938)
41 trial.ti. (136816)
42 (crossover or cross‐over or cross over).tw. (63710)
43 or/35‐42 (975081)
44 (animals not (humans and animals)).sh. (3933222)
45 43 not 44 (898007)
46 34 and 45 (27)
47 (2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$).ed. (5221872)
48 (2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$).dp. (4991743)
49 47 or 48 (5869811)
50 46 and 49 (10)
Appendix 4. EMBASE
Database: Ovid MEDLINE(R) <1980 to 2015 Week 16>
1 recombinant human chorionic gonadotropin$.tw. (72)
2 recombinant HCG.tw. (211)
3 rhCG.tw. (272)
4 r‐HCG.tw. (72)
5 rec hcg.tw. (10)
6 recombinant luteinizing hormone$.tw. (59)
7 recombinant luteinising hormone$.tw. (2)
8 recombinant LH.tw. (176)
9 rh‐LH.tw. (47)
10 rhLH.tw. (56)
11 r‐hLH.tw. (41)
12 r‐LH.tw. (75)
13 rLH.tw. (379)
14 Luveris.tw. (181)
15 lutropin alfa.tw. (27)
16 Lh recombinant.tw. (8)
17 recombinant human chorionic gonadotrophin$.tw. (27)
18 Luverisis.tw. (0)
19 LHadri.tw. (0)
20 recombinant human luteini?ing hormone$.tw. (50)
21 or/1‐20 (1273)
22 urinary human chorionic gonadotropin$.tw. (75)
23 urinary human chorionic gonadotrophin$.tw. (28)
24 urinary HCG.tw. (269)
25 u‐HCG.tw. (49)
26 uHCG.tw. (32)
27 Profasi.tw. (1323)
28 Pregnyl.tw. (1511)
29 ovidrel.tw. (223)
30 Novarel.tw. (49)
31 choriogonadotropin alfa.tw. (9)
32 Follutein.tw. (12)
33 or/22‐32 (3209)
34 21 and 33 (153)
35 Clinical Trial/ (842527)
36 Randomized Controlled Trial/ (367335)
37 exp randomization/ (65848)
38 Single Blind Procedure/ (19963)
39 Double Blind Procedure/ (119481)
40 Crossover Procedure/ (42297)
41 Placebo/ (254175)
42 Randomi?ed controlled trial$.tw. (113895)
43 Rct.tw. (16570)
44 random allocation.tw. (1394)
45 randomly allocated.tw. (22018)
46 allocated randomly.tw. (2008)
47 (allocated adj2 random).tw. (720)
48 Single blind$.tw. (15540)
49 Double blind$.tw. (149086)
50 ((treble or triple) adj blind$).tw. (437)
51 placebo$.tw. (211679)
52 prospective study/ (285117)
53 or/35‐52 (1445709)
54 case study/ (31132)
55 case report.tw. (278480)
56 abstract report/ or letter/ (919367)
57 or/54‐56 (1222810)
58 53 not 57 (1406796)
59 34 and 58 (71)
60 (2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$).em. (6866092)
61 (2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$).dp. (1071015)
62 60 or 61 (6895856)
63 59 and 62 (30)
Appendix 5. PsycINFO
Database: PsycINFO <1806 to April Week 2 2015>
1 luteini?ing hormone$.tw. (1291)
2 rh‐LH.tw. (10)
3 rhLH.tw. (1)
4 r‐LH.tw. (2)
5 recombinant.tw. (2451)
6 or/1‐5 (3751)
7 urinary.tw. (6226)
8 Pregnyl.tw. (1)
9 Follutein.tw. (2)
10 7 or 8 or 9 (6229)
11 6 and 10 (28)
12 exp reproductive technology/ (1401)
13 in vitro fertili?ation.tw. (572)
14 ivf‐et.tw. (17)
15 (ivf or et).tw. (101628)
16 icsi.tw. (51)
17 intracytoplasmic sperm injection$.tw. (42)
18 (blastocyst adj2 transfer$).tw. (4)
19 assisted reproduct$.tw. (601)
20 artificial insemination.tw. (228)
21 iui.tw. (24)
22 intrauterine insemination$.tw. (19)
23 ovulation induc$.tw. (22)
24 (ovari$ adj2 stimulat$).tw. (49)
25 ovarian hyperstimulation.tw. (10)
26 COH.tw. (75)
27 superovulat$.tw. (5)
28 infertil$.tw. (2641)
29 subfertil$.tw. (65)
30 (ovari$ adj2 induction).tw. (5)
31 or/12‐30 (105238)
32 11 and 31 (2)
Appendix 6. Clinicaltrials.gov search strategy
Database: clinicaltrials.gov <search done on 13th May 2015>
1. rhcg and uhcg (8)
2. recombinant human chorionic gonadotropin and urinary human chorionic gonadotropin (20)
3. recombinant human chorionic gonadotrophin and urinary human chorionic gonadotrophin (20)
4. r‐hcg and u‐hcg (8)
5. recombinant hcg and urinary hcg (16)
6. rec hcg and urinary hcg (2)
7. recombinant luteinizing hormone and urinary human chorionic gonadotrophin (5)
8. rLH and hCG (5)
9. rhlh and uhcg (1)
10. rh‐lh and uhcg (0)
11. recombinant luteinizing hormone and urinary human chorionic gonadotropin (5)
12. rec lh and hCG (4)
13. lh recombinant and hcg urinary (5)
14. r‐lh and u‐hcg (1)
Appendix 7. WHO ICTRP search strategy
Database: WHO ICTRP <search done on 14th May 2015>
1. rhcg and uhcg (4)
2. recombinant human chorionic gonadotropin and urinary human chorionic gonadotropin (0)
3. recombinant human chorionic gonadotrophin and urinary human chorionic gonadotrophin (1)
4. r‐hcg and u‐hcg (266)
5. recombinant hcg and urinary hcg (5)
6. rec hcg and urinary hcg (1)
7. recombinant luteinizing hormone and urinary human chorionic gonadotrophin (1)
8. rLH and hCG (4)
9. rhlh and uhcg (0)
10. rh‐lh and uhcg (0)
11. recombinant luteinizing hormone and urinary human chorionic gonadotropin (0)
12. rec lh and hCG (1)
13. lh recombinant and hcg urinary (0)
14. r‐lh and u‐hcg (21)
Study flow diagram.
Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
Forest plot of comparison: 1 rhCG versus uhCG for triggering ovulation, outcome: 1.1 Ongoing pregnancy/live birth rate per woman.
Forest plot of comparison: 1 rhCG versus uhCG for triggering ovulation, outcome: 1.2 OHSS per woman.
Forest plot of comparison: 1 rhCG versus uhCG for triggering ovulation, outcome: 1.3 Clinical pregnancy rate per woman.
Forest plot of comparison: 1 rhCG versus uhCG for triggering ovulation, outcome: 1.4 Miscarriage rate per woman.
Forest plot of comparison: 2 rhLH versus uhCG for triggering ovulation, outcome: 2.1 Ongoing pregnancy/live birth rate per woman.
Forest plot of comparison: 2 rhLH versus uhCG for triggering ovulation, outcome: 2.2 OHSS per woman.
Comparison 1 rhCG versus uhCG for triggering ovulation, Outcome 1 Ongoing pregnancy/live birth rate per woman.
Comparison 1 rhCG versus uhCG for triggering ovulation, Outcome 2 OHSS per woman.
Comparison 1 rhCG versus uhCG for triggering ovulation, Outcome 3 Clinical pregnancy rate per woman.
Comparison 1 rhCG versus uhCG for triggering ovulation, Outcome 4 Miscarriage rate per woman.
Comparison 1 rhCG versus uhCG for triggering ovulation, Outcome 5 No of oocytes retrieved per woman.
Comparison 1 rhCG versus uhCG for triggering ovulation, Outcome 6 Adverse events per woman.
Comparison 2 rhLH versus uhCG for triggering ovulation, Outcome 1 Ongoing pregnancy/live birth rate per woman.
Comparison 2 rhLH versus uhCG for triggering ovulation, Outcome 2 OHSS per woman.
Comparison 2 rhLH versus uhCG for triggering ovulation, Outcome 3 Clinical pregnancy rate per woman.
Comparison 2 rhLH versus uhCG for triggering ovulation, Outcome 4 Miscarriage rate per woman.
Comparison 2 rhLH versus uhCG for triggering ovulation, Outcome 5 No of oocytes retrieved per woman.
Comparison 2 rhLH versus uhCG for triggering ovulation, Outcome 6 Adverse events per woman.
| RhCG compared to uhCG for final oocyte maturation triggering in IVF and ICSI cycles | ||||||
| Population: women undergoing final oocyte maturation triggering in IVF and ICSI cycles | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect | No of participants | Quality of the evidence | Comments | |
| Assumed risk | Corresponding risk | |||||
| UhCG | RhCG | |||||
| Ongoing pregnancy/live birth rate per woman | 367 per 1000 | 396 per 1000 | OR 1.15 | 1136 | ⊕⊕⊕⊝ | — |
| OHSS per woman ‐ moderate to severe OHSS | 10 per 1000 | 17 per 1000 | OR 1.76 | 417 | ⊕⊕⊝⊝ | — |
| Clinical pregnancy rate per woman | 330 per 1000 | 343 per 1000 | OR 1.06 | 1806 | ⊕⊕⊕⊝ | — |
| Miscarriage rate per woman | 51 per 1000 | 37 per 1000 | OR 0.72 | 1347 | ⊕⊕⊝⊝ | — |
| Adverse events per woman | 331 per 1000 | 179 per 1000 | OR 0.52 | 561 | ⊕⊕⊕⊝ | Adverse events included: injection site pain, reaction, inflammation, nausea, vomiting, abdominal pain |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). | ||||||
| GRADE Working Group grades of evidence | ||||||
| aThe pooled effect included both the line of no effect and appreciable benefit or harm. | ||||||
| RhLH compared to uhCG for final oocyte maturation triggering in IVF and ICSI cycles | |||||
| Population: women undergoing final oocyte maturation triggering in IVF and ICSI cycles | |||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect | No of participants | Quality of the evidence | |
| Assumed risk | Corresponding risk | ||||
| UhCG | RhLH | ||||
| Ongoing pregnancy/live birth rate per woman | 371 per 1000 | 359 per 1000 | OR 0.95 | 289 | ⊕⊝⊝⊝ |
| OHSS per woman ‐ Moderate OHSS | 126 per 1000 | 107 per 1000 | OR 0.83 | 289 | ⊕⊝⊝⊝ |
| Clinical pregnancy rate per woman | 407 per 1000 | 392 per 1000 | OR 0.94 | 289 | ⊕⊝⊝⊝ |
| Miscarriage rate per woman | 36 per 1000 | 34 per 1000 | OR 0.95 | 280 | ⊕⊝⊝⊝ |
| Adverse events per woman | 1 study reported this outcome in this comparison; event numbers were similar in both groups. | 259 | — | ||
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). | |||||
| GRADE Working Group grades of evidence | |||||
| aThe pooled effect included both the line of no effect and appreciable benefit or harm. | |||||
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 1 Ongoing pregnancy/live birth rate per woman Show forest plot | 7 | 1136 | Odds Ratio (M‐H, Fixed, 95% CI) | 1.15 [0.89, 1.49] |
| 1.1 Long GnRH agonist protocol | 6 | 1017 | Odds Ratio (M‐H, Fixed, 95% CI) | 1.06 [0.80, 1.39] |
| 1.2 GnRH antagonist protocol | 1 | 119 | Odds Ratio (M‐H, Fixed, 95% CI) | 2.17 [1.00, 4.68] |
| 2 OHSS per woman Show forest plot | 8 | Odds Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 2.1 Moderate to severe OHSS | 3 | 417 | Odds Ratio (M‐H, Fixed, 95% CI) | 1.76 [0.37, 8.45] |
| 2.2 Moderate OHSS | 1 | 243 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.78 [0.27, 2.27] |
| 2.3 Mild to moderate OHSS | 2 | 320 | Odds Ratio (M‐H, Fixed, 95% CI) | 1.0 [0.42, 2.38] |
| 2.4 Undefined OHSS | 3 | 495 | Odds Ratio (M‐H, Fixed, 95% CI) | 1.18 [0.50, 2.78] |
| 3 Clinical pregnancy rate per woman Show forest plot | 13 | 1806 | Odds Ratio (M‐H, Fixed, 95% CI) | 1.06 [0.87, 1.29] |
| 3.1 Long GnRH agonist protocol | 12 | 1687 | Odds Ratio (M‐H, Fixed, 95% CI) | 1.01 [0.82, 1.24] |
| 3.2 GnRH antagonist protocol | 1 | 119 | Odds Ratio (M‐H, Fixed, 95% CI) | 1.97 [0.93, 4.18] |
| 4 Miscarriage rate per woman Show forest plot | 8 | 1196 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.72 [0.41, 1.25] |
| 4.1 Long GnRH agonist protocol | 7 | 1077 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.73 [0.41, 1.29] |
| 4.2 GnRH antagonist protocol | 1 | 119 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.5 [0.04, 5.67] |
| 5 No of oocytes retrieved per woman Show forest plot | 12 | 1744 | Mean Difference (IV, Fixed, 95% CI) | ‐0.11 [‐0.70, 0.47] |
| 5.1 Long GnRH agonist protocol | 11 | 1625 | Mean Difference (IV, Fixed, 95% CI) | ‐0.14 [‐0.73, 0.45] |
| 5.2 GnRH antagonist protocol | 1 | 119 | Mean Difference (IV, Fixed, 95% CI) | 1.20 [‐3.14, 5.54] |
| 6 Adverse events per woman Show forest plot | 5 | 561 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.52 [0.35, 0.76] |
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 1 Ongoing pregnancy/live birth rate per woman Show forest plot | 2 | 289 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.95 [0.51, 1.78] |
| 2 OHSS per woman Show forest plot | 2 | 289 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.83 [0.40, 1.70] |
| 2.1 Moderate OHSS | 2 | 289 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.83 [0.40, 1.70] |
| 3 Clinical pregnancy rate per woman Show forest plot | 2 | 289 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.94 [0.54, 1.64] |
| 4 Miscarriage rate per woman Show forest plot | 2 | 289 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.95 [0.38, 2.40] |
| 5 No of oocytes retrieved per woman Show forest plot | 2 | 103 | Mean Difference (IV, Fixed, 95% CI) | ‐1.33 [‐3.26, 0.60] |
| 6 Adverse events per woman Show forest plot | 1 | Odds Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
